NCT02595268View on ClinicalTrials.gov

A Study to Investigate the Effect of JNJ-63623872 on Pitavastatin in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
Healthy
Interventions
DRUG

Pitavastatin

Participants will receive single oral dose of pitavastatin 1 milligram (mg) on Day 1 and Day 9.

DRUG

JNJ-63623872

Participants will receive JNJ-63623872 600 mg twice daily on Days 4 through 12.

Trial Locations (1)

Unknown

Antwerp

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02595268 - A Study to Investigate the Effect of JNJ-63623872 on Pitavastatin in Healthy Participants | Biotech Hunter | Biotech Hunter